ArticleExperimental and therapeutic medicine2018
Evaluation of drug release from paclitaxel + hirudin-eluting balloons and the resulting vascular reactivity in healthy pigs.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- Recent progress on formulations of hirudin.Pharmaceutical science advances · 2025Review
- Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma.Biomedicines · 2025Review
- Recombinant hirudin and PAR-1 regulate macrophage polarisation status in diffuse large B-cell lymphoma.BMC biotechnology · 2024Article
- Recombinant hirudin attenuates pulmonary hypertension and thrombosis in acute pulmonary embolism rat model.PeerJ · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explored drug release from paclitaxel + hirudin-eluting balloons in a healthy pig coronary artery model and objectively evaluated the vascular reactivity after balloon intervention. A total of 12 healthy white pigs were used for the analysis of drug release from the experimental balloon. The observational time-points included immediately following implantation and day 7, 30, and 180 after surgery. At each time-point, two pigs were treated with the paclitaxel + hirudin-eluting balloon and one with the B. Braun paclitaxel-eluting balloon (control). Quantitative coronary angiography (QCA) of the target vessel was performed before and after balloon treatment. One pig died before the designated experimental endpoint, and no abnormal clinical signs or tissue lesions were observed in the other pigs. QCA showed different degrees of spasms after balloon treatment, all of which recovered shortly thereafter without intervention. The blood vessel lumens were all open and without dissection or angioma. Drug content determination showed that the experimental balloon performed better than the control balloon with regard to drug release, vascular absorption and expulsion rate. The paclitaxel + hirudin-eluting balloon catheter was easy to manipulate. The drug release from the experimental balloon was stable and resulted in good vascular reactivity. The safety and efficacy of the experimental balloon were not worse than the paclitaxel-eluting balloon that is currently on the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.